Clinical Trials List
2021-03-01 - 2023-12-31
Phase II
Terminated5
ICD-10K71.0
Toxic liver disease with cholestasis
ICD-10K71.10
Toxic liver disease with hepatic necrosis, without coma
ICD-10K71.11
Toxic liver disease with hepatic necrosis, with coma
ICD-10K71.2
Toxic liver disease with acute hepatitis
ICD-10K71.3
Toxic liver disease with chronic persistent hepatitis
ICD-10K71.4
Toxic liver disease with chronic lobular hepatitis
ICD-10K71.50
Toxic liver disease with chronic active hepatitis without ascites
ICD-10K71.51
Toxic liver disease with chronic active hepatitis with ascites
ICD-10K71.6
Toxic liver disease with hepatitis, not elsewhere classified
ICD-10K71.7
Toxic liver disease with fibrosis and cirrhosis of liver
ICD-10K71.8
Toxic liver disease with other disorders of liver
ICD-10K71.9
Toxic liver disease, unspecified
ICD-10K75.2
Nonspecific reactive hepatitis
ICD-10K75.3
Granulomatous hepatitis, not elsewhere classified
ICD-10K75.81
Nonalcoholic steatohepatitis (NASH)
ICD-10K75.89
Other specified inflammatory liver diseases
ICD-10K75.9
Inflammatory liver disease, unspecified
ICD-10K76.4
Peliosis hepatis
ICD-9573.3
Hepatitis, unspecified
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
110 participants